Soligenix Q2 net loss narrows as R&D expenses fall
Soligenix Q2 net loss narrows as R&D expenses fall
Overview
US biopharmaceutical firm's Q2 net loss narrowed due to reduced R&D expenses
Company reported no revenue for Q2 2026
Outlook
Company to continue seeking non-dilutive funding for Bundibugyo Ebola vaccine program
Soligenix to actively evaluate strategic options including partnerships, licensing, and M&A
Company says cash position provides runway into Q2 2028
Result Drivers
LOWER R&D EXPENSES - Net loss narrowed mainly due to reduced research and development costs after terminating the FLASH2 trial and HyBryte development activities
Company press release: ID:nPn1JQrtKa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Loss |
| $2 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Soligenix Inc is $1.75, about 362% above its August 6 closing price of $0.38
Reuters Recommended Reads
Aug 6 - ALX Oncology Q2 net loss narrows on lower R&D costs
Aug 6 - Cognition Therapeutics Q2 net loss narrows on lower R&D costs
Aug 4 - Moderna begins first human trial of Bundibugyo Ebola vaccine
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)